Inhibitors of arginase

A compound of Formula (I):

• or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof,
• wherein:
• X1 and X2 are independently N or CH;
• Y is CR1R2, CR1R2R3, —O—, —OR4, —S—, —SR5, —NR6—, or —NR6R7;
• Q is C or CR8;
• is absent or C1-C4 alkylene, wherein the C1-C4 alkylene is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• provided that:
• (i) is C1-C4 alkylene, taken together with Y and Q to form a ring, when Y is CR1R2 and Q is C;
• and (ii) is absent when Y is CR1R2R3 and Q is CR8;
• L1 is a bond or C1-C4 alkylene, wherein the C1-C4 alkylene is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• G1 is CR1a, C(O), N or NH;
• G2 is CR2a, C(O), N or NH;
• is a single bond or a double bond, provided that:
• (i) is a single bond when G1 is C(O) and G2 is NH or when G2 is C(O) and G1 is NH;
• and (ii) is a double bond when G1 is CR1a and G2 is CR2a or N, and when G1 is N and G2 is CR2a;
• G3 is CR3a or N;
• G4 is CR4a or N;
• m and n are independently 0, 1 or 2, provided that at least one of m and n is 1 or 2;
• Ra and Rb are each independently hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl, wherein the C1-C6 alkyl and C3-C8 cycloalkyl are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• or Ra and Rb are taken together with the atoms to which they are attached to form a 5- to 10-membered heterocyclyl, wherein the 5- to 10-membered heterocyclyl is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• Rc, Rd and Re are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, or C6-C14 aryl, wherein the C1-C6 alkyl, C3-C8 cycloalkyl and C6-C14 aryl are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• R1, R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, halo, C1-C6 alkyl, or C3-C8 cycloalkyl, wherein the C1-C6 alkyl and C3-C8 cycloalkyl are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• R1a, R2a, R3a and R4a are each independently hydrogen, halo, —CN, —ORf, NRgRh, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, or C6-C14 aryl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl and C6-C14 aryl are each independently unsubstituted or substituted by 1, 2, 3, or 4 groups independently selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo;
• and
• Rf, Rg, and Rh are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, or C6-C14 aryl, wherein the C1-C6 alkyl, C3-C8 cycloalkyl and C6-C14 aryl are each independently unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C1-C6 alkyl, C3-C8 cycloalkyl, —CN, —OH, and oxo.